SCHEMBL6907745

SCHEMBL6907745

CC(=O)Oc1ccc(NCC(=O)NC=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
ALDH1A1 P00352 6/20 0.47
GAA P10253 3/20 0.47
HSP90AA1 P07900 1/20 0.47
HSD17B10 Q99714 3/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 2/20 0.43
KMT2A Q03164 5/20 0.43
NLRP1 Q9C000 1/20 0.43
MEN1 O00255 4/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
ROCK2 O75116 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP3A4 P08684 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TTR P02766 1/20 0.40
TP53 P04637 1/20 0.40
ELANE P08246 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905017 0.83 MEN1 (0.50) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL6900831 0.81 MAPT (0.50) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL6907885 0.79 MAPT (0.59) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL6907646 0.79 MAPT (0.47) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL8768919 0.79 MAPT (0.58) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL11340805 0.78 MAPT (0.53) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL6902229 0.78 MAPT (0.53) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL6905909 0.78 MAPT (0.53) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL6907436 0.77 ERCC1 (0.45) MAPTALDH1A1GAAHSP90AA1HSD17B10
SCHEMBL4257353 0.77 MAPT (0.59) MAPTALDH1A1GAAHSP90AA1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 MAPT 4452/4885ALDH1A1 1110/4885GAA 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.